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Background: Adult patients with cystic fibrosis (CF) frequently have reduced exercise tolerance, which is
multifactorial but mainly due to bronchial obstruction. The aim of this retrospective analysis was to determine the
mechanisms responsible for exercise intolerance in patients with mild-to-moderate or severe disease.
Methods: Cardiopulmonary exercise testing with blood gas analysis at peak exercise was performed in 102 patients
aged 28 ± 11 years: 48 patients had severe lung disease (FEV1 < 50%, group 1) and 54 had mild-to-moderate lung
disease (FEV1 ≥ 50%, group 2). VO2 peak was measured and correlated with clinical, biological, and functional
parameters.
Results: VO2 peak for all patients was 25 ± 9 mL/kg/min (65 ± 21% of the predicted value) and was < 84% of
predicted in 82% of patients (100% of group 1, 65% of group 2). VO2 peak was correlated with body mass index,
C-reactive protein, FEV1, FVC, RV, DLCO, VE/VCO2 peak, VD/VT, PaO2, PaCO2, P(A-a)O2, and breathing reserve. In
multivariate analysis, FEV1 and overall hyperventilation during exercise were independent determinants of exercise
capacity (R2 = 0.67). FEV1 was the major significant predictor of VO2 peak impairment in group 1, accounting for
31% of VO2 peak alteration, whereas excessive overall hyperventilation (reduced or absent breathing reserve and
VE/VCO2) accounted for 41% of VO2 alteration in group 2.
Conclusion: Exercise limitation in adult patients with CF is largely dependent on FEV1 in patients with severe lung
disease and on the magnitude of the ventilatory response to exercise in patients with mild-to-moderate lung disease.
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Cystic fibrosis (CF) is characterized by deterioration of
nutritional status and irreversible loss of lung function
[1-3]. Patients with CF often experience exertional dys-
pnea and have reduced maximal exercise capacity, which
is an important predictor of mortality [4-7]. Regular
exercise in these patients has been associated with
improved aerobic exercise endurance and quality of life
[4,8]. Physical exercise requires the cardiopulmonary
system to deliver oxygen to muscles in sufficient quan-
tity to generate energy through aerobic glycolysis. There
are conflicting data on the precise mechanisms* Correspondence: benoit.wallaert@chru-lille.fr
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reproduction in any medium, provided the orunderlying exercise intolerance in CF, and a number of
factors have been implicated [9], including poor nutri-
tional status, peripheral muscle dysfunction [10,11], and
especially, ventilatory limitation [12,13]. In other stud-
ies, dysfunctional gas exchange has been shown to play
a crucial role in limiting exercise performance [14-17].
Only a third of the variability in exercise capacity of
CF patients can be explained by FEV1, demonstrating
that resting pulmonary function tests (PFTs) alone are
insufficient to explain the exercise limitation [1,9,13]. By
comparison, cardiopulmonary exercise testing (CPET)
offers a sensitive evaluation of potential physiological
disturbances in cardiovascular, respiratory, peripheral,
or neurosensory responses to a standardized exercise
protocol [18]. Although it remains underutilized in CF
[19], CPET could provide important exercise-relatedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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formance and thus assist in CF patient management
aimed at improving exercise capacity.
With this in mind, we initiated a study to determine
the mechanisms responsible for exercise limitation in
102 adult CF patients with mild-to moderate or severe
lung disease. The patients were subjected to CPET with
blood gas analysis during exercise and the results were
correlated with clinical and functional characteristics.
Methods
Patients
A total of 102 adult patients (sex ratio M:F 0.52) with
CF were enrolled at four CF centers in France: Lille (75
patients), Rouen (15 patients), Dijon (5 patients), and
Grenoble (7 patients). Written informed consent for
participation in the study was obtained from partici-
pants. Use of the patient data was approved by the local
ethics committee, and the study was considered obser-
vational and approved as such by the Institutional
Review Board of the French Learned Society for Pulmo-
nology (Société de Pneumologie de Langue Française,
CEPRO 2012 009).
Clinical, nutritional, biological, PFT, and CPET data
were obtained on the same day, either at diagnosis or at
the routine annual evaluation, and were retrospectively
collected. When patients were seen at several follow-up
visits, only the data from the first visit were recorded.
Hypoxemic patients did not perform CPET and were ex-
cluded from the analysis. A diagnosis of CF was obtained
by sweat chloride > 60 mmol/L and the presence of
CFTR gene mutations by molecular analysis. Additional
characteristics recorded at the time of testing were dis-
eases usually associated with CF, bacterial colonization,
treatments, and nutritional status, including height and
weight measurements and impedance analysis.
Cardiopulmonary testing
Forced vital capacity (FVC), forced expiratory volume in
1 s (FEV1), FEV1 to FVC ratio, total lung capacity (TLC),
and residual volume (RV) were measured by plethysmog-
raphy (Jaeger-Masterlab® cabin). Diffusing capacity of the
lung for carbon monoxide (DLCO: mL CO/min/mm Hg)
was adjusted for hemoglobin concentration in g/dL
according to Cotes’ equation: corrected (Hb) DLCO=
DLCO× (10.2 +Hb)/(1.7 × Hb). Following ATS/ERS 2005
guidelines, the lower limits of normal were set at the 5th
percentile (or predicted minus 1.64 SD) of each reference
population. The results are expressed as percentages of
the predicted values. Predicted normal values were derived
from standard equations [20-22].
PFTs and CPET were performed in an air-conditioned
laboratory (22°C constant temperature), using a stan-
dardized protocol as previously described [23,24]. TheCPET protocol was the same at each center. Each
patient underwent a symptom-limited incremental exer-
cise test on an ergometric bicycle (Ergoline-Ergometrics
800®). The protocol included a warm-up period of 3 min
at 20 W followed by a progressively increasing work
rate (WR) in a ramp fashion and then 3 min recovery.
The ramped WR increment was individualized (range,
8–30 W/min). During exercise, heart rate (HR) was
monitored continuously by 12-lead ECG, and arterial
oxygen saturation (SpO2) was measured by pulse oxim-
etry (Nellcor N-395). The expired gases were analyzed
with an Ergocard®, focusing on oxygen consumption
(VO2), carbon dioxide production (VCO2), minute ven-
tilation (VE), and tidal volume (VT). The oxygen pulse
(VO2/HR) was calculated. Measurements of PaO2 and
PaCO2 were performed on room air at rest and at peak
exercise. Normal values for PaO2 were derived from
[25]. Lactatemia was determined at maximal exercise.
Breathing reserve (BR) was calculated as BR = (predicted
maximum minute ventilation [MMV] – VE peak)/MMV,
with MMV estimated from MMV= FEV1 × 40. HR peak
was expressed as a percentage of maximum predicted
HR, calculated as HR max = 210 – (0.65 × age). Dead
space (VD/VT) was calculated according to Bohr’s equa-
tion corrected for the additional instrument dead space:
VD/VT = (PaCO2 – PECO2 mean)/PaCO2 – (VD [machine]/
VT) where PECO2 is the partial pressure of expired CO2.
Predicted values for VO2 max were calculated from
reference equations [26]. Poor motivation appeared not
to be an interfering factor in our analysis, as all patients
had at least one of the following: BR < 15%, peak HR > 90%
of predicted, peak lactate > 7 mmol/L, peak exercise
PaO2 < 55 mm Hg, and peak VE/VO2 > 35 or peak RER >
1.15 [23]. Immediately after exercise, subjects were asked
to score their sense of breathlessness and muscle fatigue
at peak exercise using Borg scales.
Statistical analysis
The continuous variables are reported as mean ± SD.
Normal distribution of quantitative variables was tested
by the Shapiro–Wilk test. Differences in FEV1 between
the groups were determined with the Student’s t-test or
Mann–Whitney test. Bivariate analyses were performed
to study the relationships between each explanatory vari-
able and the VO2 peak. Pearson’s or Spearman’s correl-
ation coefficient was used for quantitative variables, and
the Student’s t-test or Mann–Whitney test for qualitative
variables. In addition, a multivariable linear regression
with a stepwise selection at the level 0.2 was performed
to identify a subset of the most important explanatory
variables for the relationship with VO2 peak. In order to
avoid the problem of multicolinearity which happens
when the explanatory variables are highly correlated,
and to obtain a parsimonious model, we adopt the
Table 2 Resting pulmonary function tests in CF patients







FEV1 < 50% ≥ 50%
FEV1
a 60 ± 28 35 ± 9b 82 ± 18
FVCa 75 ± 24 56 ± 14b 93 ± 16
FEV1/FVC 65 ± 15 54 ± 11
b 75 ± 10
RVa 176 ± 65 220 ± 50b 135 ± 48
DLCOa 68 ± 18 56 ± 13b 78 ± 14
PaO2, mm Hg 80 ± 14 71 ± 10
b 87 ± 12
PaCO2, mm Hg 38 ± 4 38 ± 5 37 ± 4
P(A-a)O2, mm Hg 29 ± 13 38 ± 8
b 21 ± 12
aResults are expressed as mean ± SD percentage of predicted values.
bP < .0001 compared with group 2.
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selected and included in a Principal Component Analysis
(PCA) in order to study their correlations. Then, the vari-
ables included in the multivariable regression model were
selected by the results of PCA (graphic correlation circle)
on the basis of their clinical pertinence. The stability of
the model was assessed by a bootstrap method [27]. The
bootstrap resampling method was based on 1000 repli-
cates of the initial dataset. Multivariable regression with a
stepwise selection at the level 0.2 was performed on
each of these replicates. The inclusion of the variable in
the final model was confirmed if this candidate variable
was selected in at least 70% of these 1000 analyses. In
the final model, for each variable we computed the par-
tial R-square, coefficient, 95% confidence intervals and
adjusted p-value. Final variables from the multivariate
analysis were applied to each group of FEV1. All ana-
lyses were achieved with SAS software version 9.2 (SAS
Institute Inc., Cary, NC). All tests were performed at
the significant level at 0.05.
Results
Subjects
The demographic and clinical characteristics are shown in
Table 1, and the resting PFT results are presented in
Table 2. The cohort consisted of 102 CF patients with a
mean age of 28 ± 11 years (range 17–67). The time from
diagnosis to evaluation was 16 ± 10 years. For data ana-
lysis, the cohort was divided into two groups according toTable 1 Demographic and clinical characteristics of the
CF patients
ΔF 508 homozygous mutationa 31/79 (40%)
Smokera 10/102 (10%)
Oxygen supplementationa 11/95 (11%)
ABPAa 33/95 (35%)
Exocrine pancreatic insufficiencya 78/102 (76%)
Diabetesa 21/102 (21%)
Nasal polyposisa 25/94 (27%)
BMI, kg/m2b 20 (20 ± 3)
Lean body mass, kgb 45 (48 ± 9)
Pseudomonas aeruginosaa 63/99 (63%)
Staphylococcus aureus MSa 36/99 (36%)
Mycobacterium abscessa 4/99 (4%)
Blood leukocytes, 1012/mm3b 9 (9.7 ± 3.8)
Blood polymorphonuclear neutrophils, 1012/mm3b 6 (6.4 ± 3.3)
CRP, mg/Lb 5.5 (15 ± 30)
Serum albumin, g/Lb 42 (42 ± 4)
ABPA = allergic bronchopulmonary aspergillosis; BMI = body mass index;
CRP = C-reactive protein.
Qualitative variables are given as frequency and percentage.
aResults are expressed as number (percentage) of patients.
bResults are expressed as median values (mean ± SD).their FEV1: group 1 patients with severe lung disease
(FEV1 < 50%, 48 patients) and group 2 patients with mild-
to-moderate lung disease (FEV1 ≥ 50%, 54 patients). Group
1 had a significantly higher frequency of homozygosity
for the CFTR ΔF 508 mutation, pancreatic insufficiency,
bronchial colonization with Pseudomonas aeruginosa, and
biological inflammatory syndrome, and significantly lower
body mass index (BMI) and longer disease duration (data
not shown).
The patients had a range of disease severities and were
recruited from four centers in France. Patients from dif-
ferent centers all had characteristics consistent with the
French CF Registry 2009 Report [28] and showed equiva-
lent frequencies of key CF characteristics (ΔF508 muta-
tion, exocrine pancreatic insufficiency, and colonization
with P. aeruginosa), supporting the reproducibility of the
results and the potential for extrapolation to other patient
populations.
Resting PFT values (Table 2) were significantly more
altered in group 1 than in group 2 (Table 2). As expected,
three major functional abnormalities were found: ob-
structive syndrome (FEV1/FVC = 65 ± 15% of predicted),
altered distension (RV = 176 ± 65% of predicted), and
altered DLCO (68 ± 18% of predicted).
Exercise responses
Exercise cessation was mainly due to leg fatigue in com-
bination with dyspnea (62%), whereas leg fatigue alone
or dyspnea alone was observed in 17% and 21% of pa-
tients, respectively. The VO2 peak value (weight-adjusted
VO2) was decreased to < 84% of predicted in 83/102
(82%) of patients (48/48 [100%] in group 1 and 35/54
[65%] in group 2) and was significantly lower in group 1
than in group 2 (Table 3).
Analysis of the ventilatory response (VE peak, BR,
respiratory rate (RR), VT/FVC peak) highlighted the dif-
ferences according to FEV1 impairment (Table 3). Group
Table 3 Cardiopulmonary exercise tests in CF patients







FEV1 < 50% ≥ 50%
VO2 peak, mL/kg/min 25 ± 9 20 ± 5
d 30 ± 8.5
VO2 peak
a 65 ± 21 51 ± 13d 77 ± 20
Borg dyspnea 4.7 ± 1.9 5.6 ± 2b 4.1 ± 1.5
Borg Leg fatigue 4.5 ± 1.8 5.2 ± 1.8b 4.4 ± 1.7
VE peak, L/min 58 ± 22 44 ± 11d 70 ± 21
RR peak, min 41 ± 9 43 ± 9b 39 ± 8
VT/FVC peak, % 48 ± 11 47 ± 13 48.6 ± 8
VE/VO2 peak 41 ± 7 42 ± 7 41 ± 7
VE/VCO2 peak 36 ± 6 37 ± 6 35 ± 5
BR, % 24 ± 20 8 ± 11d 37.5 ± 16
VD/VT peak 0.32 ± 0.11 0.39 ± 0.07
d 0.25 ± 0.10
pH peak 7.34 ± 0.04 7.34 ± 0.04 7.35 ± 0.04
PaO2 peak, mm Hg 76 ± 16 63 ± 10
d 89 ± 12
PaCO2 peak, mm Hg 40 ± 7 44 ± 6
d 36 ± 4
P(A-a)O2 peak, mm Hg 37 ± 13 46 ± 8
d 28 ± 10
Lactatemia peak, mmol/L 7 ± 2.6 6 ± 2d 7.9 ± 3
HR peaka 82 ± 10 79 ± 8d 86 ± 9
VO2/HR peak
a 79 ± 22 67 ± 16d 90 ± 21
aResults are expressed as mean ± SD percentage of predicted values.
bP < .01 compared with group 2.
cP < .001 compared with group 2.
dP < .0001 compared with group 2.
Table 4 Correlation of clinical and functional variables
with VO2 peak in CF patients
Qualitative variables n P value
Female 102 .22
ΔF508 homozygous mutation 79 .02
Exocrine pancreatic insufficiency 102 .55
Pseudomonas aeruginosa 99 .36
Quantitative variables n Correlation (r)
Age, years 102 −0.11 .29
BMI, kg/m2* 102 0.26 .009
Leukocytosis, 109/mm3 70 −0.42 .0003
CRP, mg/L 64 −0.34 .006
Serum albumin, g/L 43 0.34 .02
FEV1
a* 102 0.71 < .0001
FVCa* 102 0.69 < .0001
RVa 79 −0.58 < .0001
DLCOa 68 0.56 < .0001
PaO2, mm Hg 98 0.43 < .0001
PaCO2, mm Hg 98 0.11 .29
Cardiopulmonary exercise parameters n Correlation (r)
VE peak, L 102 0.64 < .0001
VE/VCO2 peak* 98 −0.35 < .0001
BR, %* 102 0.37 .0001
VD/VT peak* 96 −0.64 < .0001
PaCO2 peak, mm Hg* 97 −0.45 < .0001
P(A-a)O2 peak, mm Hg* 97 −0.54 < .0001
Lactatemia peak, mmol/L* 86 0.59 < .0001
HR peaka 102 0.40 < .0001
aCorrelations based on percentage of predicted values.
*Selected variables for multivariate stepwise analysis.
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a depletion of BR. Hyperventilation was due to simultan-
eous increases in RR and tidal volume. Impairment in
pulmonary gas exchange was more severe in group 1, as
shown by higher values of P(A-a)O2, VD/VT peak, and
PaCO2, and lower values of PaO2. Cardiocirculatory
responses were normal in group 2, but patients in group
1 showed low VO2/HR values and a significant decrease
in peak HR. Four patients experienced ECG abnormal-
ities but continued with the exercise test.
Determinants of exercise capacity
Significant correlations were observed between VO2 peak
and nutritional status (BMI, lean body mass), inflamma-
tion markers (C-reactive protein [CRP], leukocytosis),
resting PFT (FVC, FEV1, RV, DLCO, P(A-a)O2), and
quantifiable parameters of CPET (VE peak, VE/VO2
peak, VE/VCO2 peak, BR, VD/VT peak, PaO2 peak, P(A-a)
O2 peak, and HR (Table 4 and Figure 1).
The results of the stepwise multiple regression analysis
for determinants of exercise capacity are shown in Table 5.
Of the variables entered into the model (BMI, FEV1, FVC,
DLCO, PaO2, VE/VCO2 peak, BR, VD/VT peak, PaO2
peak, PaCO2 peak, P(A-a)O2 peak, and lactatemia peak),only FEV1, VE/VCO2 peak, and BR were found to be inde-
pendent predictors of exercise capacity (r2 = 0.67). Ana-
lysis of these three variables showed that, for group 1, 31%
of the VO2 peak was explained by FEV1, whereas the
major determinants of the VO2 peak in group 2 were BR ,
FEV1 and VE/VCO2 peak (Table 5).
Separate analysis in the cohort of Lille (75 out of the
102 patients) showed the same results: FEV1, BR and
VE/CO2 were independent predictors of exercise cap-
acity (r2 = 0.65) (data not shown).
Discussion
Our study focused on a population of 102 adults with
CF who underwent CPET with blood gas analysis at
peak exercise. Maximal oxygen uptake was impaired in
82% of patients and was more pronounced in patients
with low FEV1. We noted a high prevalence of abnormal
exercise responses in our population, including abnor-
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Figure 1 Correlation between VO2 peak and FEV1, FVC, VE/CO2 peak, BR, P(A-a)O2 peak, and VD/VT peak in CF patients. VO2 peak, FEV1,
FVC, and BR are expressed as percentage of predicted values. P(A-a)O2 peak is expressed as mm Hg.
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from this study are that exercise intolerance in CF is
multifactorial and is correlated mainly with resting pul-
monary function, nutritional status, and inflammatory
status, but is also affected by the magnitude of the over-
all ventilatory response during exercise. Multivariate
analysis revealed that bronchial obstruction plays a dom-
inant role in patients with severe disease, whereasTable 5 Determinants of VO2 peak in CF patients
Variable All patients
(n = 102)
FEV1 50 (0.84 [0.70;0.98])
a
BR 12 (−0.62 [−0.82;-0.42])a
VE/VCO2 peak 5 (−1.13 [−1.56;-0.69])
a
Results are expressed as the partial r-square (r2), i.e. the percentage of VO2 alteratio
shown between parentheses. FEV1, VE/VCO2 peak, and BR were independent predic
peak was explained by FEV1, whereas, in group 2, BR was the major determinant ex
Results are derived from multivariable analysis.
aAdjusted p value < .0001; bp = .027; cp = .0002.excessive hyperventilation during exercise was the major
determinant of exercise limitation in patients with mild-
to-moderate disease.
CF can be associated with abnormal gas exchange,
ventilatory, cardiocirculatory, and muscular responses to
exercise [3,9,13,29]. In our study, these abnormalities
were responsible for limiting the aerobic capacity of 82%




31 (1.08 [0.70;1.45])a 18 (0.67 [0.46;0.88])a
6 (−0.36 [−0.68;-0.04])b 35 (−0.85 [−1.10;-0.59])a
15 (−0.95 [−1.41;-0.48])c 6 (−1.52 [−2.22;-0.82])a
n explained by the variable. Coefficient and 95% confidence intervals are
tors explaining 67% of exercise capacity (r2 = 0.67). In group 1, 31% of the VO2
plaining 35% of the VO2 peak.
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single exercise profile common to all patients, reflecting
the complexity of mechanisms involved in exercise limita-
tion in CF patients. Some patients showed abnormalities
predominantly in gas exchange, others in the ventilatory
response. Still others experienced exercise intolerance
despite the absence of ventilatory limitation. The rela-
tive contribution of these factors differed between the
two groups.
In our study, BMI and CRP levels were strongly corre-
lated with exercise limitation, which is consistent with
several studies indicating the importance of inflamma-
tory and nutritional status in exercise limitation. Nutri-
tional status plays a well-established role in CF exercise
intolerance [31] and prognosis [32], and may be linked
to the chronic inflammation observed in CF patients,
which is mainly due to respiratory colonization [33].
Inflammatory markers such as CRP are also negatively
associated with exercise capacity in patients with CF [7].
Moreover, inflammation is experimentally correlated
with loss of muscle mass [34] and skeletal muscle weak-
ness [10] and could explain the association observed
here between CRP, lean body mass, and reduced max-
imal oxygen uptake.
Multivariate analysis showed that FEV1 was the most
significant predictor of VO2 peak in patients with severe
lung disease. This result is consistent with data from
earlier studies [3,35] and demonstrates the predominant
role of ventilatory disorders in exercise limitation in
severe CF patients. Additional functional parameters,
such as distension, obstruction, and CO diffusion also
correlated with VO2 peak, but were not independent
predictors. The low BR exhibited by our population is
another characteristic of the exercise response in severe
CF patients. Tantisira et al. showed that the BR index
(VE/maximal voluntary ventilation calculated at ventila-
tory threshold) was the most powerful predictor of mor-
tality in CF patients awaiting lung transplantation [36].
This has also been observed in COPD [37] but is not
common to all obstructive lung diseases. For example,
McNicholl et al. reported that only 18% of severe asthma
patients had ventilatory limitation due to obstructive lung
function [38].
In contrast, the VO2 peak was not fully explained by
FEV1 in patients with mild-to-moderate lung disease,
and some patients exhibited impaired aerobic capacity
despite having normal resting lung function (Figure 1).
Indeed, multivariate analysis showed that two CPET
parameters were the major independent determinants
of VO2 peak in group 2: hyperventilation due to abnor-
mal ventilatory control, resulting in high ventilatory
equivalents (as demonstrated by VE/VO2 and VE/VCO2
peaks), and BR depletion. Exercise ventilation is regu-
lated by numerous mechanisms, most of which remainincompletely understood [39]. Hyperventilation during
exercise reflects a nonspecific response to one or more
dysfunctional links in the respiratory chain, but the main
cause is not known [40]. In some diseases, such as heart
failure, hyperventilation is recognized as a more relevant
prognostic factor than VO2 peak. The hyperventilatory
response may be due to several factors, including ineffi-
cient gas exchange as reflected by P(A-a)O2 and the
VD/VT ratio. Although hyperventilation is difficult to
relate to other abnormalities, the strong correlation of
hyperventilation with oxygen pulse and peak lactatemia
suggests that central (cardiovascular) and peripheral
(muscle) determinants play a role [10].
In our study, all patients underwent blood gas analysis
at peak effort and we noted a high prevalence of gas
exchange abnormalities during exercise. It is interesting
to note that patients with identical lung function did not
all show gas exchange abnormalities. This could be
explained by an inadequate ventilatory response in some
patients or by a high degree of ventilation-perfusion
mismatch. Exercise-induced hypoxemia was common in
our study and correlated with VO2 peak, workload, peak
VD/VT, and dyspnea assessed by the Borg scale (results
not shown). We found that P(A-a)O2 correlated well
with peak VO2, highlighting the relevance of this par-
ameter in gas exchange analysis. Other studies have
examined impairment of gas exchange during exercise
in CF patients. Nixon et al. showed that PETCO2 >
41 mm Hg at peak exercise is associated with a twofold
higher relative risk of mortality [4]. However, PETCO2 is
not a reliable marker for PaCO2 during exercise and
does not allow accurate calculation of dead space [41].
Compared with PFT, CPET with blood gas analysis at
peak exercise is better able to assess gas exchange ab-
normalities and highlight exercise hypoxemia, a recog-
nized prognosis marker, and thus gauge the need for
oxygen supplementation.
The primary limitation of our study is its retrospective
nature and the possibility of missing data. Peripheral
muscle strength was not assessed and might be a signifi-
cant contributing factor [10]. These results should be
confirmed by a prospective study.Conclusion
In conclusion, exercise limitation in adult patients with CF
correlates with respiratory function as well as nutritional
and inflammatory status. This limitation is dependent on
FEV1 in patients with severe disease but is mainly affected
by the magnitude of the ventilatory response to exercise in
patients with mild-to-moderate lung disease. CPET thus
contributes to a more comprehensive understanding of
exercise limitation and can assist in patient management
aimed at improving exercise capacity.
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